Business model to the rescue, not emerging markets
This article was originally published in Scrip
Three unconnected news stories have caught the attention of most pharma industry radars this week. On the surface, they have nothing to do with each other. Catching attention are: India’s Biocon and Pfizer terminating a biosimilar insulin alliance; Bayer losing exclusivity on cancer drug Nexavar (sorafenib tosylate) in India, which has invoked its first ever compulsory licence; and AstraZeneca’s legal fight with the FDA to extend US patent life for the blockbuster antipsychotic Seroquel (quetiapine fumarate).
You may also be interested in...
The fundamental problem with the pharmaceutical industry’s old business model could be astonishingly similar to the elusive challenge to balance healthcare quality and costs. Different times call for people to be working toward different goals. Biopharma and the healthcare system are working to the wrong goal.
Two businessmen talked intently sitting at a small white table dwarfed by an enormous video screen probably about 15 feet high and 20 feet wide. Covered in a cold bluish-red electronic glow, their meeting appeared as if it were occurring in New York City's Times Square, at night.
China - specifically its healthcare industry and market - is too often seen through the eyes of the Western companies as a manifest destiny, a promised land for new growth. This view is heavily unidirectional in that this enormous economically growing country is an open frontier upon which they will capitalize by bringing their advanced products.